KIORA PHARMACEUTICALS INC (KPRX) Stock Price, Quote, News and Overview
NASDAQ:KPRX - Nasdaq - US49721T5074 - Common Stock - Currency: USD
KPRX Quote, Performance and Key Statistics
3.03
0 (0%)
The current stock price of KPRX is 3.03 USD. In the past month the price increased by 1%. In the past year, price decreased by -27.86%.
KPRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 57.78 | 753.57B | ||
| JNJ | JOHNSON & JOHNSON | 15.13 | 365.75B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 18.55 | 300.82B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.48 | 237.64B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 15.92 | 217.25B | ||
| MRK | MERCK & CO. INC. | 10.12 | 197.94B | ||
| PFE | PFIZER INC | 7.55 | 137.81B | ||
| SNY | SANOFI-ADR | 10.7 | 117.72B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.36 | 94.94B | ||
| GSK | GSK PLC-SPON ADR | 8.6 | 78.12B | ||
| ZTS | ZOETIS INC | 25.88 | 69.36B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 62.75 | 47.04B |
Related stock screener links
About KPRX
Company Profile
Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. The company is headquartered in Encinitas, California and currently employs 12 full-time employees. The company went IPO on 2015-02-13. The firm is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). The company is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.
Company Info
KIORA PHARMACEUTICALS INC
332 Encinitas Boulevard, Suite 102
Encinitas CALIFORNIA US
CEO: Franz Obermayr
Employees: 12
Phone: 17817888869
KIORA PHARMACEUTICALS INC / KPRX FAQ
What is the stock price of KIORA PHARMACEUTICALS INC today?
The current stock price of KPRX is 3.03 USD.
What is the ticker symbol for KIORA PHARMACEUTICALS INC stock?
The exchange symbol of KIORA PHARMACEUTICALS INC is KPRX and it is listed on the Nasdaq exchange.
On which exchange is KPRX stock listed?
KPRX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for KIORA PHARMACEUTICALS INC stock?
8 analysts have analysed KPRX and the average price target is 11.22 USD. This implies a price increase of 270.3% is expected in the next year compared to the current price of 3.03. Check the KIORA PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is KIORA PHARMACEUTICALS INC worth?
KIORA PHARMACEUTICALS INC (KPRX) has a market capitalization of 9.21M USD. This makes KPRX a Nano Cap stock.
How many employees does KIORA PHARMACEUTICALS INC have?
KIORA PHARMACEUTICALS INC (KPRX) currently has 12 employees.
What are the support and resistance levels for KIORA PHARMACEUTICALS INC (KPRX) stock?
KIORA PHARMACEUTICALS INC (KPRX) has a support level at 2.97 and a resistance level at 3.12. Check the full technical report for a detailed analysis of KPRX support and resistance levels.
Is KIORA PHARMACEUTICALS INC (KPRX) expected to grow?
The Revenue of KIORA PHARMACEUTICALS INC (KPRX) is expected to decline by -86.57% in the next year. Check the estimates tab for more information on the KPRX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy KIORA PHARMACEUTICALS INC (KPRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of KPRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of KPRX, evaluating the profitability, health, valuation and growth aspects
- KIORA PHARMACEUTICALS INC (KPRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- KIORA PHARMACEUTICALS INC (KPRX) Sales and EPS estimates to see what analysts future expectations are.
- KIORA PHARMACEUTICALS INC (KPRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- KIORA PHARMACEUTICALS INC (KPRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- KIORA PHARMACEUTICALS INC (KPRX) Stock Chart to make your own analysis
- KIORA PHARMACEUTICALS INC (KPRX) Latest news and press-releases to stay up to date.
Does KIORA PHARMACEUTICALS INC (KPRX) stock pay dividends?
KPRX does not pay a dividend.
When does KIORA PHARMACEUTICALS INC (KPRX) report earnings?
KIORA PHARMACEUTICALS INC (KPRX) will report earnings on 2025-08-07.
What is the Price/Earnings (PE) ratio of KIORA PHARMACEUTICALS INC (KPRX)?
KIORA PHARMACEUTICALS INC (KPRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.9).
What is the Short Interest ratio of KIORA PHARMACEUTICALS INC (KPRX) stock?
The outstanding short interest for KIORA PHARMACEUTICALS INC (KPRX) is 0.61% of its float. Check the ownership tab for more information on the KPRX short interest.
KPRX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to KPRX. When comparing the yearly performance of all stocks, KPRX is a bad performer in the overall market: 83.54% of all stocks are doing better.
KPRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to KPRX. The financial health of KPRX is average, but there are quite some concerns on its profitability.
KPRX Financial Highlights
Over the last trailing twelve months KPRX reported a non-GAAP Earnings per Share(EPS) of -2.9. The EPS increased by 81.8% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.42% | ||
| ROE | -50.85% | ||
| Debt/Equity | 0 |
KPRX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to KPRX. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of -347.64% and a revenue growth -86.57% for KPRX